Literature DB >> 22180617

Localized production of IL-10 suppresses early inflammatory cell infiltration and subsequent development of IFN-γ-mediated Lyme arthritis.

F Lynn Sonderegger1, Ying Ma, Heather Maylor-Hagan, James Brewster, Xiaosong Huang, Gerald J Spangrude, James F Zachary, John H Weis, Janis J Weis.   

Abstract

IL-10 is a nonredundant inflammatory modulator that suppresses arthritis development in Borrelia burgdorferi-infected mice. Infected C57BL/6 (B6) IL-10(-/-) mice were previously found to have a prolonged IFN-inducible response in joint tissue. Infection of B6 IL-10 reporter mice identified macrophages and CD4(+) T cells as the primary sources of IL-10 in the infected joint tissue, suggesting that early local production of IL-10 dampened the proarthritic IFN response. Treatment of B6 IL-10(-/-) mice with anti-IFN-γ reduced the increase in arthritis severity and suppressed IFN-inducible transcripts to wild-type levels, thereby linking dysregulation of IFN-γ to disease in the B6 IL-10(-/-) mouse. Arthritis in B6 IL-10(-/-) mice was associated with elevated numbers of NK cell, NKT cell, α/β T cell, and macrophage infiltration of the infected joint. FACS lineage sorting revealed NK cells and CD4(+) T cells as sources of IFN-γ in the joint tissue of B6 IL-10(-/-) mice. These findings suggest the presence of a positive-feedback loop in the joint tissue of infected B6 IL-10(-/-) mice, in which production of inflammatory chemokines, infiltration of IFN-γ-producing cells, and additional production of inflammatory cytokines result in arthritis. This mechanism of arthritis is in contrast to that seen in C3H/He mice, in which arthritis development is linked to transient production of type I IFN and develops independently of IFN-γ. Due to the sustained IFN response driven by NK cells and T cells, we propose the B6 IL-10(-/-) mouse as a potential model to study the persistent arthritis observed in some human Lyme disease patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22180617      PMCID: PMC3262892          DOI: 10.4049/jimmunol.1102359

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Gene expression profiling reveals unique pathways associated with differential severity of lyme arthritis.

Authors:  Hillary Crandall; Diane M Dunn; Ying Ma; R Mark Wooten; James F Zachary; John H Weis; Robert B Weiss; Janis J Weis
Journal:  J Immunol       Date:  2006-12-01       Impact factor: 5.422

Review 2.  Therapy for Lyme arthritis: strategies for the treatment of antibiotic-refractory arthritis.

Authors:  Allen C Steere; Sheryn M Angelis
Journal:  Arthritis Rheum       Date:  2006-10

3.  Phagocytosis of Borrelia burgdorferi and Treponema pallidum potentiates innate immune activation and induces gamma interferon production.

Authors:  Meagan W Moore; Adriana R Cruz; Carson J LaVake; Amanda L Marzo; Christian H Eggers; Juan C Salazar; Justin D Radolf
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

4.  The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America.

Authors:  Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman
Journal:  Clin Infect Dis       Date:  2006-10-02       Impact factor: 9.079

5.  Signaling through CD14 attenuates the inflammatory response to Borrelia burgdorferi, the agent of Lyme disease.

Authors:  Mohammed Rafii-El-Idrissi Benhnia; Danielle Wroblewski; Muhammad Naveed Akhtar; Raina A Patel; Wendy Lavezzi; Sophie C Gangloff; Sanna M Goyert; Melissa J Caimano; Justin D Radolf; Timothy J Sellati
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

6.  Interleukin-10 anti-inflammatory response to Borrelia burgdorferi, the agent of Lyme disease: a possible role for suppressors of cytokine signaling 1 and 3.

Authors:  Vida A Dennis; Ayanna Jefferson; Shree R Singh; Frédéric Ganapamo; Mario T Philipp
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Expression of interleukin-10 in intestinal lymphocytes detected by an interleukin-10 reporter knockin tiger mouse.

Authors:  Masahito Kamanaka; Sean T Kim; Yisong Y Wan; Fayyaz S Sutterwala; Maria Lara-Tejero; Jorge E Galán; Ed Harhaj; Richard A Flavell
Journal:  Immunity       Date:  2006-11-30       Impact factor: 31.745

8.  Rapid and sensitive quantification of Borrelia burgdorferi-infected mouse tissues by continuous fluorescent monitoring of PCR.

Authors:  T B Morrison; Y Ma; J H Weis; J J Weis
Journal:  J Clin Microbiol       Date:  1999-04       Impact factor: 5.948

9.  Experimental lyme arthritis in the absence of interleukin-4 or gamma interferon.

Authors:  C R Brown; S L Reiner
Journal:  Infect Immun       Date:  1999-07       Impact factor: 3.441

10.  IL-10 deficiency promotes increased Borrelia burgdorferi clearance predominantly through enhanced innate immune responses.

Authors:  John J Lazarus; Michelle J Meadows; Robert E Lintner; R Mark Wooten
Journal:  J Immunol       Date:  2006-11-15       Impact factor: 5.422

View more
  27 in total

1.  Induction of Interleukin 10 by Borrelia burgdorferi Is Regulated by the Action of CD14-Dependent p38 Mitogen-Activated Protein Kinase and cAMP-Mediated Chromatin Remodeling.

Authors:  Bikash Sahay; Kathleen Bashant; Nicole L J Nelson; Rebeca L Patsey; Shiva Kumar Gadila; Rebecca Boohaker; Ashutosh Verma; Klemen Strle; Timothy J Sellati
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

2.  Robust interferon signature and suppressed tissue repair gene expression in synovial tissue from patients with postinfectious, Borrelia burgdorferi-induced Lyme arthritis.

Authors:  Robert B Lochhead; Sheila L Arvikar; John M Aversa; Ruslan I Sadreyev; Klemen Strle; Allen C Steere
Journal:  Cell Microbiol       Date:  2018-10-17       Impact factor: 3.715

3.  CD4+ T cells promote antibody production but not sustained affinity maturation during Borrelia burgdorferi infection.

Authors:  Rebecca A Elsner; Christine J Hastey; Nicole Baumgarth
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

4.  Lysosomal β-glucuronidase regulates Lyme and rheumatoid arthritis severity.

Authors:  Kenneth K C Bramwell; Ying Ma; John H Weis; Xinjian Chen; James F Zachary; Cory Teuscher; Janis J Weis
Journal:  J Clin Invest       Date:  2013-12-16       Impact factor: 14.808

5.  Interferon-gamma production in Lyme arthritis synovial tissue promotes differentiation of fibroblast-like synoviocytes into immune effector cells.

Authors:  Robert B Lochhead; David Ordoñez; Sheila L Arvikar; John M Aversa; Luke S Oh; Benton Heyworth; Ruslan Sadreyev; Allen C Steere; Klemen Strle
Journal:  Cell Microbiol       Date:  2019-01-04       Impact factor: 3.715

6.  Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis.

Authors:  Emily S Hansen; Velinka Medić; Joseph Kuo; Thomas F Warner; Ronald F Schell; Dean T Nardelli
Journal:  Infect Immun       Date:  2013-09-16       Impact factor: 3.441

7.  IL-10 Deficiency Reveals a Role for TLR2-Dependent Bystander Activation of T Cells in Lyme Arthritis.

Authors:  Sarah K Whiteside; Jeremy P Snook; Ying Ma; F Lynn Sonderegger; Colleen Fisher; Charisse Petersen; James F Zachary; June L Round; Matthew A Williams; Janis J Weis
Journal:  J Immunol       Date:  2018-01-12       Impact factor: 5.422

8.  Invariant natural killer T cells act as an extravascular cytotoxic barrier for joint-invading Lyme Borrelia.

Authors:  Woo-Yong Lee; Maria-Jesus Sanz; Connie H Y Wong; Pierre-Olivier Hardy; Aydan Salman-Dilgimen; Tara J Moriarty; George Chaconas; Adriana Marques; Roman Krawetz; Christopher H Mody; Paul Kubes
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-09       Impact factor: 11.205

Review 9.  Lyme disease: aetiopathogenesis, factors for disease development and control.

Authors:  I R Kean; K L Irvine
Journal:  Inflammopharmacology       Date:  2012-10-31       Impact factor: 4.473

Review 10.  Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response.

Authors:  Ervin Ç Mingomataj; Alketa H Bakiri
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.